Journal of Clinical Oncology
Articles in this Issue
Trends in gynaecological cancer incidence in Singapore over the last two decades.
217 Background: Singapore has witnessed a significant rise in cancer incidence among women over recent decades, particular...
Real-world validation of a Lynch syndrome screening model in a multi-ethnic Asian cohort with dMMR tumors.
169 Background: Current Lynch syndrome (LS) screening relies on mismatch repair (MMR) status. To optimize LS screening, we...
Olanzapine-based, dexamethasone-free antiemetic prophylaxis for highly emetogenic chemotherapy in children and adolescents: A multicenter phase III non-inferiority trial (CIVIC-POD).
304 Background: Guidelines recommend dexamethasone combined with a 5-HT3 receptor antagonist and a neurokinin-1 antagonist...
A two-step pre-treatment screening strategy combining enzyme phenotyping and targeted DPYD genotyping: A pragmatic approach for preventing fluoropyrimidine toxicity.
306 Background: Severe fluoropyrimidine toxicity is linked to reduced DPD activity. Universal DPYD genotyping has low sens...
Integrated analysis of miRNA–mRNA regulatory crosstalk: Insights from the miR-296-3p and DDHD2 network in breast cancer.
61 Background: Breast cancer remains a leading cause of cancer-related morbidity and mortality among women worldwide, with...
LEN-EOS study: Lenalidomide-associated eosinophilia as a marker of response to induction therapy in multiple myeloma.
250 Background: Lenalidomide is an immunomodulatory drug which play an integral role in induction therapy in multiple myel...
Predictive value of clinical complete response to neoadjuvant chemotherapy in trimodality therapy for muscle invasive bladder cancer.
185 Background: For patients with muscle-invasive bladder cancer (MIBC) treated with bladder-preserving trimodality therap...
Multi-mechanism armored B7H3/IL13Ra2 bispecific CAR-T for treatment of glioblastoma.
70 Background: Glioblastoma (GBM) is an aggressive and highly lethal cancer characterized by diffuse infiltration, molecul...
Choosing the optimal neoadjuvant backbone for HER2-positive breast cancer: A multicenter real-world comparison of AC-THP and TCHP in Vietnam.
58 Background: In the era of dual HER2 blockade, the optimal neoadjuvant chemotherapy backbone for HER2-positive breast ca...
Breast cancer mHealth apps across treatment and survivorship: A systematic review of directly evaluated content and features.
60 Background: Breast cancer survivors report ongoing information and self-management needs from diagnosis through treatme...
The PAN-SUR(IN) score for advanced pancreatic cancer: A comprehensive analysis of methodology, prognostic derivation, and clinical risk stratification.
116 Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by late presentation and aggressive biology. Howe...
Early molecular kinetics to predict deep molecular response and inform frontline TKI selection in pediatric chronic myeloid leukemia: A real-world multicenter study.
254 Background: The prognostic utility of adult-derived scoring systems and early molecular response (EMR, defined as...
Efficacy and safety of first-line PD-1/PD-L1 inhibitor–based therapy in esophageal squamous cell carcinoma: A systematic review and meta-analysis.
113 Background: First-line treatment of esophageal squamous cell carcinoma (ESCC) has evolved with PD-1/PD-L1 inhibitor–ba...
Real-world genomic profiling of endometrial cancer in south India to identify clinically actionable alterations.
206 Background: Endometrial cancer exhibits substantial molecular heterogeneity with important implications for prognosis...
Efficacy of psychological intervention in children with cancer: A randomized controlled trial.
333 Background: Pediatric cancer patients often experience significant psychological distress due to their diagnosis, trea...
Prognostic value of the pre-treatment systemic inflammation response index (SIRI) for progression-free survival in EGFR-mutant advanced lung adenocarcinoma.
292 Background: Although EGFR-tyrosine kinase inhibitors (TKIs) serve as the cornerstone of treatment for advanced lung ad...
Validation and feasibility of symptom management toolkit among cancer survivors and caregivers in India.
351 Background: Cancer survivors receiving treatment or on follow-up face substantial burden of managing their symptoms. M...
Serum laminin γ2 monomer (LG2m) to reflect a CD90-driven immunosuppressive niche and survival benefit from atezolizumab plus bevacizumab in hepatocellular carcinoma.
310 Background: Atezolizumab plus bevacizumab (A+B) improves survival compared with sorafenib (Sora) in advanced hepatocel...
Anisamide-conjugated PLGA nanoparticles for targeted co-delivery of sorafenib and paclitaxel in colorectal cancer.
85 Background: Colorectal cancer continues to be one of the leading cancers, ranking third in occurrence and second in can...
Beyond PSA and PSMA: Defining PSA–PSMA discordance for FDG PET and genomic stratification in mCRPC.
194 Background: PSA kinetics and PSMA PET guide mCRPC response, yet PSA–PSMA discordance occurs in ~20–30% of patients. We...
From neuroscience to oncology: Multi-agent AI replicating neural reasoning architecture for evidence-based colon cancer clinical decisions.
17 Background: Colorectal cancer management requires integration of complex genomic data, clinical guidelines, and patient...
Disproportionality analysis of musculoskeletal and connective tissue disorders associated with aromatase inhibitors: A real-world pharmacovigilance study.
51 Background: Aromatase inhibitors (AIs) are a cornerstone of endocrine therapy for hormone receptor-positive breast canc...
Flux-coupled network pharmacology to identify AR–HIF1A–mTOR tri-axis as a mechanistic vulnerability in genitourinary (GU) cancers.
8 Background: Advanced genitourinary cancers are driven by intertwined androgen receptor (AR) signaling, HIF-1α-mediated h...
Comparative efficacy and safety of first-line systemic combinations for advanced urothelial carcinoma: A Bayesian network meta-analysis.
184 Background: The phase 3 EV-302 trial established enfortumab vedotin plus pembrolizumab (EV+P) as the new first-line (1...
Host determinants of adjuvant chemotherapy feasibility and survival in localized upper gastrointestinal adenocarcinoma.
125 Background: Perioperative chemotherapy improves survival in resectable gastric and gastroesophageal junction (GEJ) ade...